Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

被引：4

作者：

Garnock-Jones, Karly P. ^{[1
]}

Keating, Gillian M. ^{[1
]}

Scott, Lesley J. ^{[1
]}

机构：

[1] Adis, Auckland, New Zealand

来源：

BIODRUGS | 2010年 / 24卷 / 03期

关键词：

COMPLEX-FORMATION; HERCEPTIN; CHEMOTHERAPY; DOXORUBICIN; INHIBITION; MODULATION; PACLITAXEL; MECHANISM; ANTIBODY; SUBTYPES;

D O I：

10.2165/11204680-000000000-00000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：207 / 209

页数：3

共 50 条

[1] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer
Karly P. Garnock-Jones
Gillian M. Keating
Lesley J. Scott
BioDrugs, 2010, 24 : 207 - 209
[2] Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Garnock-Jones, Karly P.
Keating, Gillian M.
Scott, Lesley J.
DRUGS, 2010, 70 (02) : 215 - 239
[3] Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer
KP Garnock-Jones
GM Keating
LJ Scott
Drugs, 2011, 71 : 1578 - 1578
[4] Clinical and echocardiographic predictors of early trastuzumab cardiotoxicity in adjuvant treatment of positive human epidermal growth factor receptor type 2 (HER2) breast cancer
Piotrowski, G.
Gawor, R.
Strzelecki, P.
Potemski, P.
Gawor, Z.
EUROPEAN HEART JOURNAL, 2013, 34 : 1063 - 1063
[5] TrastuzumabA Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer
Karly P. Garnock-Jones
Gillian M. Keating
Lesley J. Scott
Drugs, 2010, 70 : 215 - 239
[6] Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (vol 70, pg 215, 2010)
Garnock-Jones, K. P.
Keating, G. M.
Scott, L. J.
DRUGS, 2011, 71 (12) : 1578 - 1578
[7] Tailored duration of adjuvant trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer
Yu, Ke-Da
Zhou, Zhi-Rui
Shao, Zhi-Ming
CANCER RESEARCH, 2020, 80 (04)
[8] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
Piotrowski, G.
Gawor, R.
Potemski, P.
Gawor, Z.
EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
[9] ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS
Essers, B. A.
Tjan, Heijnen, V
Severens, J. L.
Novak, A.
Oron, U.
Pompen, M.
Joore, M. A.
VALUE IN HEALTH, 2008, 11 (06) : A472 - A472
[10] De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.
Goldvaser, Hadar
Yasmin, Korzets Ceder
Shepshelovich, Daniel
Yerushalmi, Rinat
Sarfaty, Michal
Ribnikar, Domen
Thavendiranathan, Paaladinesh
Amir, Eitan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →